These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24002097)

  • 1. Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model.
    Stucki A; Acosta F; Cottagnoud M; Cottagnoud P
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5808-10. PubMed ID: 24002097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis.
    Stucki A; Cottagnoud M; Acosta F; Egerman U; Laeuffer JM; Cottagnoud P
    J Antimicrob Chemother; 2012 Mar; 67(3):661-5. PubMed ID: 22178642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.
    Stucki A; Cottagnoud M; Acosta F; Egerman U; Läuffer J; Cottagnoud P
    Antimicrob Agents Chemother; 2012 Feb; 56(2):921-5. PubMed ID: 22064544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant streptococcus pneumoniae in an experimental rabbit meningitis model.
    Cottagnoud P; Cottagnoud M; Acosta F; Stucki A
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4653-5. PubMed ID: 23836180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
    Pichardo C; Rodríguez-Martínez JM; Pachón-Ibañez ME; Conejo C; Ibáñez-Martínez J; Martínez-Martínez L; Pachón J; Pascual A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3311-6. PubMed ID: 16048941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
    Bhalodi AA; Crandon JL; Williams G; Nicolau DP
    Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.
    Zemelman C; Bello H; Domínguez M; González G; Mella S; Zemelman R
    Diagn Microbiol Infect Dis; 2001; 40(1-2):41-3. PubMed ID: 11448562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro bactericidal activity of cefepime and cefpirome against clinical isolates at Karachi.
    Arsalan A; Naqvi SB; Ali SA; Ahmed S; Shakeel O
    Pak J Pharm Sci; 2015 May; 28(3):841-7. PubMed ID: 26004702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E. coli, K. pneumoniae and K. oxytoca community-acquired infections susceptibility to cephalosporins and other antimicrobials in Lebanon.
    Moghnieh RA; Musharrafieh UM; Husni RN; Abboud E; Haidar M; Abboud E; Abou Shakra D
    J Med Liban; 2014; 62(2):107-12. PubMed ID: 25011373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular characteristics of cefepime-susceptible Escherichia coli and Klebsiella spp. isolates with a positive β-lactamase screening test result but negative confirmation.
    Hu F; Wu W; Ye X; Xu X; Zhu D
    Eur J Clin Microbiol Infect Dis; 2010 Oct; 29(10):1297-9. PubMed ID: 20549530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
    BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefepime against extended spectrum p-lactamase-producing Escherichia coli and Klebsiella pneumoniae from clinical specimens at Bugando Medical Centre, Mwanza, Tanzania.
    Mshana SE; Kidenya BR; Kataraihya JB
    Tanzan J Health Res; 2011 Oct; 13(4):119-21. PubMed ID: 26592057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is There an Association Between Use of Amoxicillin-Clavulanate and Resistance to Third-Generation Cephalosporins in Klebsiella pneumoniae and Escherichia coli at the Hospital Level?
    Marquet A; Vibet MA; Caillon J; Javaudin F; Chapelet G; Montassier E; Batard E
    Microb Drug Resist; 2018 Sep; 24(7):987-994. PubMed ID: 29489447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.
    Sader HS; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2558-63. PubMed ID: 26856825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.
    Housman ST; Keel RA; Crandon JL; Williams G; Nicolau DP
    Antimicrob Agents Chemother; 2012 May; 56(5):2576-80. PubMed ID: 22330908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.